Teriflunomide
| Evidence Level: N/A | Predicted Indications: 0 |
Table of Contents
- Teriflunomide
Teriflunomide: Known uses and market status in India
Summary
The TxGNN model produced candidates for Teriflunomide, but every candidate that can be traced to a source is already a known use. There is therefore currently no new predicted indication for this drug. The one known use is listed below with its source.
Quick overview
| Item | Content |
|---|---|
| New predicted indications | None (all traceable model candidates are known uses) |
| Known uses among model candidates | 1 |
| Evidence level | Not applicable |
| India Market Status | Listed in a compiled Indian medicine price dataset (7 of 7) – CDSCO approval status is not included in this data |
| Number of Listed Products | 7 (valid: 7) |
Known uses among the model’s candidates
Approved (supported by a licence or label)
| Indication | Source |
|---|---|
| relapsing-remitting multiple sclerosis | Licence in another country (approved indication: multiple sclerosis) |
Related to an approved indication (same disease category)
| Indication | Approved category |
|---|---|
| none | none |
Relations recorded in the knowledge graph (no approval found)
| Indication |
|---|
| none |
India Market Information
| Licence | Product | Dosage form | Status |
|---|---|---|---|
| 201075 | Scleteri 14mg Tablet | strip of 10 tablets | Valid |
| 142149 | Merosya 14mg Tablet | strip of 10 tablets | Valid |
| 202008 | Scleteri 7mg Tablet | strip of 10 tablets | Valid |
| 220381 | Teru MS 7mg Tablet | strip of 10 tablets | Valid |
| 139823 | Merosya 7 Tablet | strip of 10 tablets | Valid |
| 217034 | Teru MS 14mg Tablet | strip of 10 tablets | Valid |
| 61180 | Denopsy 14mg Tablet | strip of 14 tablets | Valid |
Safety Considerations
- Drug Interactions: 561 interactions were recorded. Major-level examples include:
- Corticosteroids: hydrocortisone, dexamethasone, betamethasone, budesonide, triamcinolone
- Antidiabetic agents: acarbose, pioglitazone
- Others: acetylsalicylic acid, bupropion, clarithromycin, minocycline, chenodeoxycholic acid, oxandrolone, oxymetholone
Moderate-level examples include alosetron, cimetidine, empagliflozin and sitagliptin.
Package insert warnings and contraindications were not available in the data compiled for this report. Please refer to the package insert for further safety information.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.